Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and netilmicin

levofloxacin has been researched along with netilmicin in 13 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(netilmicin)		Trials
(netilmicin)		Recent Studies (post-2010) (netilmicin)
4,3465812,2091,10819055

Protein Interaction Comparison

ProteinTaxonomylevofloxacin (IC50)netilmicin (IC50)
30S ribosomal protein S6Escherichia coli K-120.02
30S ribosomal protein S7Escherichia coli K-120.02
50S ribosomal protein L15Escherichia coli K-120.02
50S ribosomal protein L10Escherichia coli K-120.02
50S ribosomal protein L11Escherichia coli K-120.02
50S ribosomal protein L7/L12Escherichia coli K-120.02
50S ribosomal protein L19Escherichia coli K-120.02
50S ribosomal protein L1Escherichia coli K-120.02
50S ribosomal protein L20Escherichia coli K-120.02
50S ribosomal protein L27Escherichia coli K-120.02
50S ribosomal protein L28Escherichia coli K-120.02
50S ribosomal protein L29Escherichia coli K-120.02
50S ribosomal protein L31Escherichia coli K-120.02
50S ribosomal protein L31 type BEscherichia coli K-120.02
50S ribosomal protein L32Escherichia coli K-120.02
50S ribosomal protein L33Escherichia coli K-120.02
50S ribosomal protein L34Escherichia coli K-120.02
50S ribosomal protein L35Escherichia coli K-120.02
50S ribosomal protein L36Escherichia coli K-120.02
30S ribosomal protein S10Escherichia coli K-120.02
30S ribosomal protein S11Escherichia coli K-120.02
30S ribosomal protein S12Escherichia coli K-120.02
30S ribosomal protein S13Escherichia coli K-120.02
30S ribosomal protein S16Escherichia coli K-120.02
30S ribosomal protein S18Escherichia coli K-120.02
30S ribosomal protein S19Escherichia coli K-120.02
30S ribosomal protein S20Escherichia coli K-120.02
30S ribosomal protein S2Escherichia coli K-120.02
30S ribosomal protein S3Escherichia coli K-120.02
30S ribosomal protein S4Escherichia coli K-120.02
30S ribosomal protein S5Escherichia coli K-120.02
30S ribosomal protein S8Escherichia coli K-120.02
30S ribosomal protein S9Escherichia coli K-120.02
50S ribosomal protein L13Escherichia coli K-120.02
50S ribosomal protein L14Escherichia coli K-120.02
50S ribosomal protein L16Escherichia coli K-120.02
50S ribosomal protein L23Escherichia coli K-120.02
30S ribosomal protein S15Escherichia coli K-120.02
50S ribosomal protein L17Escherichia coli K-120.02
50S ribosomal protein L21Escherichia coli K-120.02
50S ribosomal protein L30Escherichia coli K-120.02
50S ribosomal protein L6Escherichia coli K-120.02
30S ribosomal protein S14Escherichia coli K-120.02
30S ribosomal protein S17Escherichia coli K-120.02
30S ribosomal protein S1Escherichia coli K-120.02
50S ribosomal protein L18Escherichia coli K-120.02
50S ribosomal protein L2Escherichia coli K-120.02
50S ribosomal protein L3Escherichia coli K-120.02
50S ribosomal protein L24Escherichia coli K-120.02
50S ribosomal protein L4Escherichia coli K-120.02
50S ribosomal protein L22Escherichia coli K-120.02
50S ribosomal protein L5Escherichia coli K-120.02
30S ribosomal protein S21Escherichia coli K-120.02
50S ribosomal protein L25Escherichia coli K-120.02
50S ribosomal protein L36 2Escherichia coli K-120.02

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (69.23)29.6817
2010's4 (30.77)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Courvalin, P; Galimand, M; Périchon, B1
Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, MA; Walsh, TR1
Lombardo, F; Obach, RS; Waters, NJ1
Cattoir, V; Nordmann, P; Poirel, L1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Bai, N; Cai, Y; Li, R; Liang, B; Liu, Y; Wang, R1
Glen, RC; Lowe, R; Mitchell, JB1
Colino Gandarillas, CI; Lanao, JM; Sánchez Navarro, A; Santos Martínez Martínez, M1
Gandarillas, CI; Martínez Lanao, J; Martínez Martínez, MS; Sánchez Navarro, A1
Blanco, AR; Papa, V; Spoto, CG; Sudano Roccaro, A1

Other Studies

13 other study(ies) available for levofloxacin and netilmicin

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Amino Acid Motifs; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Conjugation, Genetic; Conserved Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Genes, rRNA; Methylation; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Norfloxacin; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid

2007
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7

    Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; Codon, Terminator; Cross Infection; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Hospitals; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Pseudomonas putida; Transcription, Genetic

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10

    Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:9

    Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Colistin; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Mutation

2010
Predicting phospholipidosis using machine learning.
    Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5

    Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine

2010
Influence of flow rate on the disposition of levofloxacin and netilmicin in the isolated rat lung.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2005, Volume: 24, Issue:4

    Topics: Animals; In Vitro Techniques; Levofloxacin; Lung; Male; Netilmicin; Ofloxacin; Perfusion; Rats; Rats, Wistar

2005
Comparative study of the disposition of levofloxacin, netilmicin and cefepime in the isolated rat lung.
    The Journal of pharmacy and pharmacology, 2005, Volume: 57, Issue:7

    Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Kinetics; Levofloxacin; Lung; Male; Netilmicin; Ofloxacin; Organ Culture Techniques; Rats; Rats, Wistar; Respiration, Artificial; Tissue Distribution

2005
Susceptibility of methicillin-resistant Staphylococci clinical isolates to netilmicin and other antibiotics commonly used in ophthalmic therapy.
    Current eye research, 2013, Volume: 38, Issue:8

    Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Chloramphenicol; Drug Resistance; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Netilmicin; Quinolines; Staphylococcus epidermidis; Tobramycin; Vancomycin

2013